Cited by 752Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismLipid metabolism and disorders

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Open access

Cannon, Christopher P., Shah, Sukrut, Dansky, Hayes M., Davidson, Michael, Brinton, Eliot A., Gotto, Antonio M., Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B., Zafarino, Jennifer, Mitchel, Yale, Barter, Philip·2010·New England Journal of Medicine

DOI 10.1056/nejmoa1009744

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety profile of anacetrapib in patients with coronary heart disease or at high risk for coronary heart disease. Eligible patients who were taking a statin and who had an LDL cholesterol level that was consistent with that recommended in guidelines were assigned to receive 100 mg of anacetrapib or placebo daily for 18 months. The primary end points were the percent change from baseline in LDL cholesterol at 24 weeks (HDL cholesterol level was a secondary end point) and the safety and side-effect profile of anacetrapib through 76 weeks. Cardiovascular events and deaths were prospectively adjudicated. RESULTS: A total of 1623 patients underwent randomization. By 24 weeks, the LDL cholesterol level had been reduced from 81 mg per deciliter (2.1 mmol per liter) to 45 mg per deciliter (1.2 mmol per liter) in the anacetrapib group, as compared with a reduction from 82 mg per deciliter (2.1 mmol per liter) to 77 mg per deciliter (2.0 mmol per liter) in the placebo group (P<0.001)--a 39.8% reduction with anacetrapib beyond that seen with placebo. In addition, the HDL cholesterol level increased from 41 mg per deciliter (1.0 mmol per liter) to 101 mg per deciliter (2.6 mmol per liter) in the anacetrapib group, as compared with an increase from 40 mg per deciliter (1.0 mmol per liter) to 46 mg per deciliter (1.2 mmol per liter) in the placebo group (P<0.001)--a 138.1% increase with anacetrapib beyond that seen with placebo. Through 76 weeks, no changes were noted in blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo. Prespecified adjudicated cardiovascular events occurred in 16 patients treated with anacetrapib (2.0%) and 21 patients receiving placebo (2.6%) (P = 0.40). The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib. CONCLUSIONS: Treatment with anacetrapib had robust effects on LDL and HDL cholesterol, had an acceptable side-effect profile, and, within the limits of the power of this study, did not result in the adverse cardiovascular effects observed with torcetrapib. (Funded by Merck Research Laboratories; ClinicalTrials.gov number, NCT00685776.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1009744

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citation
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citation
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
Forrest, M. J., Bloomfield, D. M., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.229 · Cited by 293
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M. S., Côté, J., Rosko, K., Chavez-Eng, C. M., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 275

Flagged first, then by citations

Show all 17 references

Sorted by citations

Items 301–400 of 752

Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis
Rehman, W. U., Yarkoni, M., Ilyas, M. A., Athar, F., Javaid, M., Ehsan, M. T., Khalid, M. T., Pasha, A. K., Selma, A. B., Yarkoni, A., et al. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050152 · Cited by 26
High Density Lipoprotein: Assembly, Structure, Cargo, and Functions
Murphy, A. J. (2013) · ISRN Physiology · doi:10.1155/2013/186365 · Cited by 26
Model-Based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor
Krishna, R., Bergman, A. J., Green, M., Dockendorf, M. F., Wagner, J. A., & Dykstra, K. H. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9254-0 · Cited by 26
Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia
Dansky, H. M., Bloomfield, D. M., Gibbons, P. H., Liu, S., Sisk, C. M., Tribble, D. L., McKenney, J. M., Littlejohn, T. W., & Mitchel, Y. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.010 · Cited by 26
Self-citation
Lipoprotein (a): Coming of Age at Last
Witztum, J. L., & Ginsberg, H. N. (2016) · Journal of Lipid Research · doi:10.1194/jlr.e066985 · Cited by 26
Progress in HDL-Based Therapies for Atherosclerosis
Chyu, K., Peter, A., & Shah, P. K. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0189-9 · Cited by 25
Advances in non-invasive drug delivery for atherosclerotic heart disease
Maranhão, R. C., & Tavares, E. R. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.999663 · Cited by 25
Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol: A Randomized Controlled Trial
Toth, P. P. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.05.026 · Cited by 25
Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9
Page, M. M., Stefanutti, C., Sniderman, A. D., & Watts, G. F. (2015) · Clinical Science · doi:10.1042/cs20140755 · Cited by 25
Evidence of dependence of lipoprotein(a) on triglyceride and high-density lipoprotein metabolism
Konerman, M. C., Kulkarni, K. R., Toth, P. P., & Jones, S. R. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.08.004 · Cited by 25
Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk
Noto, D., Cefalu, A. B., & Averna, M. R. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0414-4 · Cited by 26
Lowering cholesterol in chronic kidney disease: is it safe and effective?
Wong, M. G., Wanner, C., Knight, J. F., & Perkovic, V. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv393 · Cited by 25
CETP‐Inhibition and HDL‐Cholesterol: A Story of CV Risk or CV Benefit, or Both
Nicholls, S. J. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1118 · Cited by 25
Impact of Lipoprotein (a) Levels on Long-Term Outcomes in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction
Shitara, J., Kasai, T., Konishi, H., Endo, H., Wada, H., Doi, S., Naito, R., Tsuboi, S., Ogita, M., Dohi, T., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-18-0970 · Cited by 25
Learning lessons from Pfizer's $800 million failure
(2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3401 · Cited by 25
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0429-3 · Cited by 26
New therapies to reduce low-density lipoprotein cholesterol
Wierzbicki, A. S., Viljoen, A., Hardman, T. C., & Mikhailidis, D. P. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283605fa2 · Cited by 24
Severe familial hypercholesterolaemia: Current and future management
Farnier, M., & Bruckert, É. (2012) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2012.05.011 · Cited by 24
High-density lipoprotein levels and risk of cardiovascular events
Mureddu, G. F., Brandimarte, F., & Luca, L. D. (2011) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32834bb3c8 · Cited by 26
Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review.
Franchini, M., Capuzzo, E., & Liumbruno, G. M. (2016) · Europe PMC (PubMed Central) · doi:10.2450/2015.0163-15 · Cited by 24
Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
Metzinger, M. P., Saldanha, S., Gulati, J. S., Patel, K. V., El‐Ghazali, A., Deodhar, S., Joshi, P. H., Ayers, C. R., & Rohatgi, A. K. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018136 · Cited by 26
The role of HDL in plaque stabilization and regression
Feig, J. E., Feig, J. L., & Dangas, G. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000408 · Cited by 25
Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib
Hegele, R. A., & Goldberg (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s34976 · Cited by 24
New and Emerging LDL Cholesterol–Lowering Drugs
Kosmas, C. E., & Frishman, W. H. (2014) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000063 · Cited by 23
Upregulating Reverse Cholesterol Transport With Cholesteryl Ester Transfer Protein Inhibition Requires Combination With the LDL-Lowering Drug Berberine in Dyslipidemic Hamsters
Briand, F., Thiéblemont, Q., Muzotte, E., & Sulpice, T. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.252932 · Cited by 23
Blood Pressure Lowering Effect of Cuban Policosanol is Accompanied by Improvement of Hepatic Inflammation, Lipoprotein Profile, and HDL Quality in Spontaneously Hypertensive Rats
Cho, K., Yadav, D., Kim, S., & Kim, J. (2018) · Molecules · doi:10.3390/molecules23051080 · Cited by 23
CETP inhibitors and cardiovascular disease: Time to think again
Miller, N. E. (2014) · F1000Research · doi:10.12688/f1000research.4396.1 · Cited by 22
Treatment of Familial Hypercholesterolemia: Is There a Need Beyond Statin Therapy?
Raper, A. C., Kolansky, D. M., & Cuchel, M. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0215-y · Cited by 22
Evaluation of plasma PCSK9 concentrations, transcript of LDL receptor, as well as the total number of monocyte LDL receptors in acute coronary syndrome patients
Burchardt, P., Rzeźniczak, J., Dudziak, J., Dżumak, A., Marchlewski, T., Ganowicz-Kaatz, T., Popiak, M., Słomczyński, M., Jezierski, M., Laskowski, W., et al. (2016) · Cardiology Journal · doi:10.5603/cj.a2016.0068 · Cited by 22
Lipoproteínas de alta densidad y reducción de riesgo cardiovascular: ¿promesas o realidades?
Santos‐Gallego, C. G., & Badimón, J. J. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.10.021 · Cited by 22
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
Filippatos, T. D., Kei, A. A., & Elisaf, M. (2017) · Diseases · doi:10.3390/diseases5040021 · Cited by 22
Identification of a potent and metabolically stable series of fluorinated diphenylpyridylethanamine-based cholesteryl ester transfer protein inhibitors
Miller, M. M., Liu, Y., Jiang, J., Johnson, J. A., Kamau, M. G., Nirschl, D. S., Wang, Y., Harikrishnan, L. S., Taylor, D. S., Chen, A. Y. A., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.011 · Cited by 22
Constitutive inhibition of plasma CETP by apolipoprotein C1 is blunted in dyslipidemic patients with coronary artery disease
Pillois, X., Gautier, T., Bouillet, B., de Barros, J.-P. P., Jeannin, A., Vergès, B. L., Bonnet, J., & Lagrost, L. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m022988 · Cited by 22
Niacin at 56 Years of Age — Time for an Early Retirement?
Giugliano, R. P. (2011) · New England Journal of Medicine · doi:10.1056/nejme1112346 · Cited by 22
High-density lipoprotein cholesterol raising
Schofield, J. D., France, M. W., Ammori, B. J., Liu, Y., & Soran, H. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328362210d · Cited by 24
Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase
Simic, B., Mocharla, P., Crucet, M., Osto, E., Kratzer, A., Stivala, S., Kühnast, S., Speer, T., Doycheva, P., Princen, H. M. G., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.01.011 · Cited by 23
Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E
Millar, J. S., Lassman, M. E., Thomas, T. A., Ramakrishnan, R., Jumes, P. A., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m074880 · Cited by 21
The Inherited Hypercholesterolemias
Loh, W. J., & Watts, G. F. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.006 · Cited by 21
LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?
Besseling, J., van Capelleveen, J. C., Kastelein, J. J. P., & Hovingh, G. K. (2013) · Drugs · doi:10.1007/s40265-013-0028-0 · Cited by 21
Lipoprotein(a) as a therapeutic target in cardiovascular disease
Koschinsky, M. L., & Boffa, M. B. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.920326 · Cited by 22
HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions
Ganjali, S., Momtazi‐Borojeni, A. A., Banach, M., Kovanen, P. T., Gotto, A. M., & Sahebkar, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.014 · Cited by 21
Self-citation
Will Cholesteryl Ester Transfer Protein Inhibition Succeed Primarily by Lowering Low-Density Lipoprotein Cholesterol?
Kathiresan, S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.967 · Cited by 21
High-Density Lipoprotein Cholesterol as the Holy Grail
Cannon, C. P. (2011) · JAMA · doi:10.1001/jama.2011.1687 · Cited by 21
Self-citation
The mystery of evacetrapib - why are CETP inhibitors failing?
Nicholls, S. J., & Bubb, K. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1745633 · Cited by 21
High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review
Chen, Q., Abudukeremu, A., Li, K., Zheng, M., Li, H., Huang, T., Huang, C., Wen, K., Wang, Y., & Zhang, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147856 · Cited by 22
Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein
Han, S., LeVoci, L., Fischer, P. A., Wang, S., Gagen, K., Chen, Y., Xie, D., Fisher, T. S., Ehrhardt, A. G., Peier, A. M., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.12.008 · Cited by 21
Cardiovascular defense challenges at the basic, clinical, and population levels
Kovacic, J. C., Castellano, J. M., & Fuster, V. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06495.x · Cited by 20
Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia
Lee, P., & Hegele, R. A. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.822485 · Cited by 20
CETP Inhibitor Torcetrapib Promotes Reverse Cholesterol Transport in Obese Insulin‐Resistant CETP‐ApoB100 Transgenic Mice
Briand, F., Thiéblemont, Q., André, A., Ouguerram, K., & Sulpice, T. (2011) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00344.x · Cited by 20
Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study
Gotto, A. M., & Moon, J. E. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.82 · Cited by 19
Self-citation
Cholesteryl Ester Transfer Protein Inhibitors
McLain, J. H., Alsterda, A. J., & Arora, R. R. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416662349 · Cited by 20
The relationship between serum levels of LOX-1 ligand containing ApoAI as a novel marker of dysfunctional HDL and coronary artery calcification in middle-aged Japanese men
Hirata, A., Kakino, A., Okamura, T., Usami, Y., Fujita, Y., Kadota, A., Fujiyoshi, A., Hisamatsu, T., Kondo, K., Segawa, H., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.013 · Cited by 19
Recent lipoprotein(a) trials
Wei, T. L., & Cho, L. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000856 · Cited by 19
CETP Inhibitors: Should We Continue to Pursue This Pathway?
Nicholls, S. J., & Nelson, A. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01070-2 · Cited by 19
Lipoprotein (a)
Durrington, P. N., Schofield, J. D., Siahmansur, T. J., & Soran, H. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000096 · Cited by 20
Hyperlipoproteinemia(a): Clinical significance and treatment options
Berthold, H. K., & Gouni‐Berthold, I. (2013) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2012.10.037 · Cited by 19
Update on the detection and treatment of atherogenic low-density lipoproteins
Sniderman, A. D., & Kwiterovich, P. O. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835ed9cb · Cited by 19
In vivo effects of anacetrapib on preβ HDL: improvement in HDL remodeling without effects on cholesterol absorption
Wang, S., Daniels, E., Chen, Y., Castro‐Perez, J. M., Zhou, H., Akinsanya, K., Previs, S. F., Roddy, T. P., & Johns, D. G. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m041541 · Cited by 19
Assessment of established HDL-C loci for association with HDL-C levels and type 2 diabetes in Pima Indians
Nair, A. K., Piaggi, P., McLean, N. A., Kaur, M., Kobes, S., Knowler, W. C., Bogardus, C., Hanson, R. L., & Baier, L. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3835-x · Cited by 19
Can we revive CETP-inhibitors for the prevention of cardiovascular disease?
Nicholls, S. J., Ray, K. K., Nelson, A. J., & Kastelein, J. J. P. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000854 · Cited by 19
High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients
Cotter, A. G., Satchell, C. S., O’Halloran, J. A., Feeney, E. R., Sabin, C. A., & Mallon, P. W. G. (2011) · AIDS · doi:10.1097/qad.0b013e32834507f0 · Cited by 19
Low High-Density Lipoprotein Cholesterol and Low/Normal Body Mass Index Are Associated With Increased Mortality in Coronary Artery Disease Patients in Taiwan
Lin, G., Li, Y.-H., Lin, C., Wang, J., & Han, C. (2013) · Circulation Journal · doi:10.1253/circj.cj-12-1511 · Cited by 18
Clinical trials with cholesteryl ester transfer protein inhibitors
Bartolo, B. A. D., Duong, M., & Nicholls, S. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000352 · Cited by 18
Lipoprotein(a): A Lipoprotein Whose Time Has Come
Kelly, E. M., & Hemphill, L. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0549-z · Cited by 19
Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis
Chaiyasothi, T., Nathisuwan, S., Dilokthornsakul, P., Vathesatogkit, P., Thakkinstian, A., Reid, C. M., Wongcharoen, W., & Chaiyakunapruk, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00547 · Cited by 19
Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties
Váchal, P., Duffy, J. L., Campeau, L., Amin, R. P., Mitra, K., Murphy, B. A., Shao, P. P., Sinclair, P. J., Ye, F., Katipally, R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00959 · Cited by 18
The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins
Friedrich, S., Kastelein, J. J. P., James, D. E., Waterhouse, T., Nissen, S. E., Nicholls, S., & Krueger, K. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.70 · Cited by 17
Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia
Aguchem, R. N., Okagu, I. U., Okorigwe, E. M., Uzoechina, J. O., Nnemolisa, S. C., & Ezeorba, T. P. C. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122823 · Cited by 17
High-Density Lipoprotein and Cardiovascular Risk Reduction: Promises and Realities
Santos‐Gallego, C. G., & Badimón, J. J. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.10.023 · Cited by 17
How Anacetrapib Inhibits the Activity of the Cholesteryl Ester Transfer Protein? Perspective through Atomistic Simulations
Äijänen, T., Koivuniemi, A., Javanainen, M., Rissanen, S., Róg, T., & Vattulainen, I. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003987 · Cited by 17
Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis
Hourcade‐Potelleret, F., Laporte, S., Lehnert, V., Delmar, P., Benghozi, R., Torriani, U., Koch, R., & Mismetti, P. (2015) · Heart · doi:10.1136/heartjnl-2014-306691 · Cited by 17
Therapeutic management of hyperlipoproteinemia (a)
Kosmas, C. E., Sourlas, A., Mallarkey, G., Silverio, D., Garcia, D. Y., Montan, P. D., Guzman, E., & Garcia, M. J. (2019) · Drugs in Context · doi:10.7573/dic.212609 · Cited by 17
Novel Treatments for Cardiovascular Disease Prevention
Huffman, M. D., & Bhatnagar, D. (2011) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2011.00280.x · Cited by 17
Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study
Ferrières, J., Lautsch, D., Ambegaonkar, B. M., Ferrari, G. M. D., Vyas, A., Baxter, C. A., Bash, L. D., Velkovski-Rouyer, M., Horack, M., Almahmeed, W. A., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.06.008 · Cited by 18
HDL as a Treatment Target: Should We Abandon This Idea?
Bègue, F., Apalama, M. L., Lambert, G. C., & Meilhac, O. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01176-1 · Cited by 16
Diagnosis and Management of Familial Dyslipoproteinemias
Kwiterovich, P. O. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0371-5 · Cited by 16
An Update On the Clinical Development of Dalcetrapib (RO4607381), a Cholesteryl Ester Transfer Protein Modulator That Increases HDL Cholesterol Levels
Rhainds, D., Arsenault, B. J., Brodeur, M. R., & Tardif, J. (2012) · Future Cardiology · doi:10.2217/fca.12.25 · Cited by 16
Lomitapide: a novel drug for homozygous familial hypercholesterolemia
Panno, M. D., Cefalu, A. B., & Averna, M. R. (2014) · Clinical Lipidology · doi:10.2217/clp.13.74 · Cited by 16
CETP Inhibition in CVD Prevention: an Actual Appraisal
Bartolo, B. A. D., Takata, K., Duong, M., & Nicholls, S. J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0724-y · Cited by 16
Pharmacological interventions in human HDL metabolism
Balder, J.-W., Staels, B., & Kuivenhoven, J. A. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000018 · Cited by 16
Should raising high-density lipoprotein cholesterol be a matter of debate?
Athyros, V. G., Katsiki, N., Karagiannis, A. I., & Mikhailidis, D. P. (2012) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3283522422 · Cited by 16
Discovery of Substituted Biphenyl Oxazolidinone Inhibitors of Cholesteryl Ester Transfer Protein
Thompson, C. F., Ali, A., Quraishi, N., Lu, Z., Hammond, M. L., Sinclair, P. J., Anderson, M. S., Eveland, S. S., Guo, Q., Hyland, S. A., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100309n · Cited by 16
A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol
Ballantyne, C. M., Shah, S., Sapre, A., Ashraf, T. B., Tobias, S. C., Şahı̇n, T., Ye, P., Dong, Y., Sheu, W. H., Kang, D., et al. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.03.255 · Cited by 16
Self-citation
Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia
Cicero, A. F. G., Bove, M., & Borghi, C. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1416094 · Cited by 17
Antibodies against HDL Components in Ischaemic Stroke and Coronary Artery Disease
Batuca, J. R., Amaral, M., Favas, C., Justino, G. C., Papoila, A. L., Ames, P. R. J., & Alves, J. D. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1645857 · Cited by 16
High-density lipoprotein cholesterol efflux capacity and incidence of coronary artery disease and cardiovascular mortality: a systematic review and meta-analysis
Cheng, W., Rosołowski, M., Boettner, J., Desch, S., Jobs, A., Thiele, H., & Buttner, P. G. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01657-3 · Cited by 16
Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Chicago, Estados Unidos, 13-17 de noviembre de 2010)
y, P. A., Bayés‐Genís, A., de Isla, L. P., Sanchís, J. M., & Heras, M. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2010.12.001 · Cited by 15
Integrating multiple traits for improving polygenic risk prediction in disease and pharmacogenomics GWAS
Zhai, S., Guo, B., Wu, B., Mehrotra, D. V., & Shen, J. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad181 · Cited by 15
Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis
Wu, B. J., Shrestha, S., Ong, K. L., Johns, D. G., Dunn, L., Hou, L., Barter, P. J., & Rye, K. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.014 · Cited by 15
Self-citation
Screening for and Management of Elevated Lp(a)
Boffa, M. B., & Koschinsky, M. L. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0417-8 · Cited by 15
Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities
Fuchs, F. D., Fuchs, Moreira, & Gus (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s32585 · Cited by 15
Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype
Cenarro, A., Puzo, J., Ferrando, J., Mateo‐Gállego, R., Bea, A. M., Calmarza, P., Jarauta, E., & Civeira, F. (2013) · Metabolism · doi:10.1016/j.metabol.2013.10.014 · Cited by 15
Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [13C8]‐evacetrapib as a tracer
Cannady, E. A., Aburub, A., Ward, C., Hinds, C., Czeskis, B. A., Ruterbories, K. J., Suico, J. G., Royalty, J. E., Ortega, D., Pack, B. W., et al. (2015) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3358 · Cited by 15
Integrated microRNA-gene analysis of coronary artery disease based on miRNA and gene expression profiles
Xu, X., & Li, H. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4936 · Cited by 16
Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia
Teramoto, T., Daida, H., Ikewaki, K., Arai, H., Maeda, Y., Nakagomi, M., Shirakawa, M., Watanabe, Y., Kakikawa, T., Numaguchi, H., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.009 · Cited by 15
The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines
Harris, J. E. (2022) · Health Policy and Technology · doi:10.1016/j.hlpt.2022.100619 · Cited by 16
Dalcetrapib in Patients with an Acute Coronary Syndrome
Schwartz, G. G., OLSSON, A. G., & Barter, P. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1300057 · Cited by 15
Self-citation
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol
Ballantyne, C. M., Shah, S., Kher, U. A., Hunter, J. A., Gill, G. G., Cressman, M. D., Ashraf, T. B., Johnson‐Levonas, A. O., & Mitchel, Y. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.10.032 · Cited by 14
Self-citation
Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol
Bishop, B. M. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31828b8463 · Cited by 15
Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease
Joseph, P. G., & Teo, K. K. (2011) · Current Cardiology Reports · doi:10.1007/s11886-011-0190-5 · Cited by 14

Authors: Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., Zafarino, J., Mitchel, Y., & Barter, P.
Affiliations: Brigham and Women's Hospital (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Radiant Research (United States) (US)
University of Utah (US)
The Heart Research Institute (AU)
ORCID: Cannon, Christopher P.
Dansky, Hayes M.
Davidson, Michael
Brinton, Eliot A.
Gotto, Antonio M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2010-12-16
Volume: 363
Issue: 25
Pages: 2406-2415
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1009744
OpenAlex: W2090464684
Cited by: 749
References: 17
Citations by year: 2026: 13 · 2025: 7 · 2024: 13 · 2023: 13 · 2022: 16 · 2021: 18 · 2020: 18 · 2019: 21 · 2018: 26 · 2017: 54 · 2016: 68 · 2015: 83 · 2014: 83 · 2013: 92 · 2012: 116
FWCI: 107.18
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords: anacetrapib, cholesteryl ester transfer protein inhibitors, coronary artery disease, LDL cholesterol lowering, HDL cholesterol, statin combination therapy, cardiovascular safety, cardiovascular events, drug safety, high-risk patients, lipid-lowering therapy, blood pressure, electrolytes, aldosterone, Bayesian hierarchical model, cardiovascular hospitalization
MeSH terms: Adult, Aged, Anticholesteremic Agents, Bayes Theorem, Combined Modality Therapy, Coronary Disease, Double-Blind Method, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Oxazolidinones, Cholesterol Ester Transfer Proteins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks